1. Short title This Act may be cited as the Orange Book Transparency Act of 2019 . 2. Orange Book (a) Patents Clause (iii) of section 505(j)(7)(A) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(7) ) is amended to read as follows: (iii) (I) When patent information submitted under subsection (b) or (c) respecting a drug included on the list is to be published by the Secretary, the Secretary shall, in revisions made under clause (ii), include such information for such drug. (II) The Secretary— (aa) shall include on the list, from such patent information respecting a drug, drug substance (including active ingredient) patents, drug product (including formulation and composition) patents, and method of use patents; and (bb) may choose to include on the list additional patent information respecting the drug. (III) The Secretary shall not include on the list any patent to the extent such patent claims a device that is used for the delivery of the drug. Notwithstanding the preceding sentence, the Secretary may require (under other applicable provisions of law) the holder of the approved application for a drug to submit, for purposes other than the list under this paragraph, patent information respecting a device that is used for the delivery of the drug. . (b) Listing of exclusivities Subparagraph (A) of section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(7) ) is amended by adding at the end the following: (iv) For each drug included on the list, the Secretary shall specify each exclusivity period that is applicable and has not concluded under— (I) clause (iii) or (iv) of subsection (c)(3)(E) of this section; (II) clause (iv) or (v) of paragraph (5)(B) of this subsection; (III) clause (iii) or (iv) of paragraph (5)(F) of this subsection; (IV) section 505A; (V) section 505E